TORONTO, March 16 /PRNewswire/ - Biosign Technologies Inc. (TSXV: BIO), a medical device company, and Peconic Bay Medical Center of Riverhead, New York, announced an agreement today to implement Biosign's Healthanywhere solution for remote patient management.
Peconic Bay Medical Center Home Health Services ("Peconic") will undertake an assessment of the application and processes of remote patient monitoring of both acute post-discharge and long-term cases. The initial focus will be on a "Health at Home" program for remote monitoring of patients with diabetes, cardiovascular disease, and respiratory disease to support Peconic's commitment to maximizing the health, comfort, mobility, and independence of each and every patient through direct skilled care and education. Initially, Peconic will deploy short-term remote monitoring that will serve acute post-discharge patients. The long-term goal is to service the needs of chronic patients, including the need for self-management.
Under this agreement, Peconic will use Biosign's Healthanywhere to provide a sustainable "Health at Home" solution for short-term remote monitoring of post-discharge patients with a baseline of vital signs for participating patients. Biosign's Healthanywhere will also be utilized for trending the health impact of remote monitoring, education, and behavioral changes affected by the program.
"The Peconic Bay Medical Center is an award-winning facility, with a reputation for using advanced medical technologies to increase the quality of care. We look forward to a successful implementation of our Healthanywhere solution in this center of clinical excellence", stated Biosign's CEO, Peter Tassiopoulos.
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT® medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information, please visit www.biosign.com
About Peconic Bay Medical Center
Peconic Bay Medical Center, a 182-bed not-for-profit medical center, includes a 60-bed Skilled Nursing and Rehabilitation Center, Peconic Bay Physical Therapy & Rehabilitation Center and Peconic Bay Home Health Services, a certified home health agency. Located in Riverhead, NY, the hospital serves nearly 120,000 residents of the East End of Long Island from Wading River to Mattituck on the North Fork and from Moriches to Hampton Bays on the South Fork since 1951. With 1,200 employees and a 200-member medical staff, PBMC provides comprehensive healthcare services on the East End. Each year Peconic Bay Medical Center discharges nearly 6,000 adult, pediatric and newborn patients and the Emergency Department treats some 26,000 patients. Peconic Bay Home Health Services provides nursing assistance with approximately 20,000 home visits each year. PBMC surgeons keep the operating rooms busy with nearly 3,700 surgeries, both inpatient and outpatient and 3,000 endoscopies. The Maternity Unit brings about 450 new babies into the world and the Skilled Nursing and Rehabilitation Center provides care for about 650 people annually. For more information, please visit www.peconicbaymedicalcenter.org
Forward-Looking Statements This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Biosign Technologies Inc.